Avanir (AVNR) Reports Publication of Superior Results from AVP-923 Phase III Dosage Study
Go back to Avanir (AVNR) Reports Publication of Superior Results from AVP-923 Phase III Dosage Study| Avanir Pharmaceuticals, Inc. Class A (NASDAQ: AVNR) | Delayed: 16.96 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $16.96 | 52 Week High | $17.05 | |||
| Open | $5.00 | 52 Week Low | $3.02 | |||
| Day High | $16.96 | P/E | N/A | |||
| Day Low | $16.96 | EPS | $-0.52 | |||
| Volume | 705,037 | |||||
